Biochemical inhibition by auranofin has not been observed with GPX4, a monomeric isoform, but recent studies have shown decreased GPX4 expression in mutant p53 non-small cell lung cancer following auranofin treatment [41,43]. This evidence concerns the gene GPX4 and non-small cell lung carcinoma.